Novel |
CD84 |
CD84 molecule |
- Cell surface interactions at the vascular wall
|
|
|
Novel |
CREG1 |
cellular repressor of E1A stimulated genes 1 |
|
|
|
Novel |
HCRTR1 |
hypocretin receptor 1 |
- Orexin and neuropeptides FF and QRFP bind to their respective receptors
- G alpha (q) signalling events
|
|
|
Novel |
PRRX1 |
paired related homeobox 1 |
|
|
|
Novel |
SERPINC1 |
serpin family C member 1 |
- Intrinsic Pathway of Fibrin Clot Formation
- Common Pathway of Fibrin Clot Formation
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Post-translational protein phosphorylation
|
- Ardeparin
- Fondaparinux
- Heparin
- Enoxaparin
- N-Formylmethionine
- SR-123781A
- Sulodexide
- Danaparoid
- Dalteparin
- Tinzaparin
- Nadroparin
- Copper
- Protamine sulfate
- Bemiparin
- Antithrombin III human
|
|
Novel |
THOC1 |
THO complex 1 |
- Transport of Mature mRNA derived from an Intron-Containing Transcript
- mRNA 3'-end processing
- RNA Polymerase II Transcription Termination
|
|
|
Novel |
TM4SF1 |
transmembrane 4 L six family member 1 |
|
|
|
|
AGTR1 |
angiotensin II receptor type 1 |
- Peptide ligand-binding receptors
- G alpha (q) signalling events
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
- Valsartan
- Olmesartan
- Losartan
- Candesartan cilexetil
- Eprosartan
- Telmisartan
- Irbesartan
- Forasartan
- Saprisartan
- Tasosartan
- CYT006-AngQb
- Azilsartan medoxomil
- Fimasartan
- Angiotensin II
- Candesartan
|
|
|
BACE1 |
beta-secretase 1 |
|
- MMI-175
- CTS-21166
- N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide
- N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE
- N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide
- 4-(4-FLUOROBENZYL)PIPERIDINE
- N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide
- 6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE
- 6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE
- N~3~-BENZYLPYRIDINE-2,3-DIAMINE
- N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE
- N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE
- 4-(2-aminoethyl)-2-cyclohexylphenol
- 4-(2-aminoethyl)-2-ethylphenol
- 4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine
- (6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one
- 2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one
- (2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol
- N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
- N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
- (2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide
- (2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide
- N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
- (6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one
- N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE
- N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE
- 3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE
- Verubecestat
|
|
|
BARD1 |
BRCA1 associated RING domain 1 |
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
|
|
|
|
BRCA1 |
BRCA1 DNA repair associated |
- Meiotic synapsis
- SUMOylation of DNA damage response and repair proteins
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- TP53 Regulates Transcription of DNA Repair Genes
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Transcriptional Regulation by E2F6
- Meiotic recombination
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
|
|
- Breast cancer
- Ovarian cancer
|
|
CRIP2 |
cysteine rich protein 2 |
|
|
|
|
DDAH2 |
dimethylarginine dimethylaminohydrolase 2 |
|
|
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
|
- Choriocarcinoma
- Gastric cancer
- Bladder cancer
- Oral cancer
- Glioma
- Laryngeal cancer
- Cervical cancer
- Esophageal cancer
|
|
EZH2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
- PRC2 methylates histones and DNA
- Oxidative Stress Induced Senescence
- PKMTs methylate histone lysines
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Transcriptional Regulation by E2F6
- HCMV Early Events
|
|
|
|
FXYD1 |
FXYD domain containing ion transport regulator 1 |
- Ion homeostasis
- Ion transport by P-type ATPases
- Potential therapeutics for SARS
|
|
|
|
FXYD7 |
FXYD domain containing ion transport regulator 7 |
- Ion homeostasis
- Ion transport by P-type ATPases
- Potential therapeutics for SARS
|
|
|
|
GCH1 |
GTP cyclohydrolase 1 |
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
- Primary torsion dystonia (PTD)
- Phenylketonuria (PKU); Hyperphenylalaninemia, BH4-deficient
|
|
HTR2B |
5-hydroxytryptamine receptor 2B |
- Serotonin receptors
- G alpha (q) signalling events
|
- Methysergide
- Cabergoline
- Zolmitriptan
- Dihydroergotamine
- Methylergometrine
- Chlorpromazine
- Triflupromazine
- Amoxapine
- Fenfluramine
- Lisuride
- Ergotamine
- Apomorphine
- Paroxetine
- Paroxetine
- Minaprine
- Cyclobenzaprine
- Ergoloid mesylate
- Tegaserod
- Doxepin
- Pergolide
- Bromocriptine
- Ketamine
- Aripiprazole
- Chlorprothixene
- Clomipramine
- Yohimbine
- Midomafetamine
- Lysergic acid diethylamide
- OPC-28326
- Epicept NP-1
- PRX-08066
- Cariprazine
- Mianserin
- Pizotifen
- Asenapine
- Ocaperidone
- Esmirtazapine
- Pipamperone
- Setiptiline
- Dihydroergocornine
- Gilteritinib
- Tiapride
- Dihydroergocristine
|
|
|
KMT2B |
lysine methyltransferase 2B |
- PKMTs methylate histone lysines
- RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
|
|
|